ArticleNPJ breast cancer2019

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?

Noam Pondé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.